MICHAEL J. DAVIS, Chief Judge.
This matter is before the Court on Defendants' Amended Motion to Dismiss. [Docket No. 16] The Court heard oral argument on December 8, 2010. The Court grants in part and denies in part Defendants' motion.
According to the Amended Complaint:
Plaintiff BioE LLC ("BioE") is a Minnesota limited liability company with its principal place of business in Minnesota. BioE is a biomedical company in the business of commercializing human umbilical cord blood stem cells and associated tools and techniques for therapeutic and pharmaceutical use. Its principal product is a cord blood processing system that comprises three bags and connecting tubing (the "Product").
Defendant Mediatech, Inc. ("Mediatech") is a Virginia corporation with its principal place of business in Virginia. Mediatech manufactures products for the medical, pharmaceutical, and biotech industries.
Defendant James DeOlden is the President and founder of Mediatech and a resident of Virginia.
In fall 2004, BioE had not yet determined how it would manufacture two of the Product's three bags, the connecting tubing, or various clamps and ports attached to the bags, fill the bags with reagent, or assemble the Product prior to shipment to customers. BioE contacted Mediatech in October 2004. During the 2004 and 2005 discussions between BioE and Mediatech, Mediatech made various allegedly false representations regarding its ability to manufacture the Product for BioE.
On August 30, 2005, BioE and Mediatech entered into a Supply Agreement (the "Agreement"). The Agreement provided that Mediatech would manufacture, sell, and deliver products to BioE in compliance with BioE's specifications, which had yet to be determined. The Agreement contemplated that Mediatech and BioE would establish the Product's specifications as it was being developed. BioE and Mediatech began producing prototypes in late 2005.
BioE considered visual inspection for particulate matter to be highly important. By mid-2006, the parties incorporated into the Agreement a requirement that the Product should be 100% free of visual particles and that Mediatech would visually inspect each bag set it produced and reject any that contained visible particles.
During BioE's clinical trials, which commenced in August 2006, Mediatech produced multiple lots of bag sets that contained visible white particles or black particulate matter. Mediatech notified BioE of the problem with these lots. Mediatech investigated and determined that the white particles were denatured protein particles created inside the bags when its filling machinery got too hot. To remedy the problem, Mediatech changed its processes and protocols to allow the filling machine to cool between bags.
On multiple occasions, DeOlden represented that the change to Mediatech's process solved the white particle problem. The white particle problem continued, and Mediatech eventually installed a cooling system on the filling machine.
In November 2007, after Mediatech represented to BioE that it had resolved all issues, BioE submitted its application for Food and Drug Administration ("FDA") clearance for the Product. In December 2007, Mediatech delivered a lot of filled bags for BioE to sell to a customer. In January 2008, before BioE delivered the bag sets to the customer, Mediatech informed BioE that the lot contained non-sterilized bag sets. This rendered the entire lot unusable and caused BioE to delay its shipment to the customer.
In December 2008, BioE received its 510(k) clearance. In February 2009, Mediatech delivered to BioE bag sets from two new lots that it had produced. BioE discovered that the bags were contaminated with particles visible from several feet away and notified Mediatech of this problem. Mediatech re-inspected all bags from one of the lots and delivered the lot to BioE with the certification that it was free of visible particles. BioE inspected this lot and found that 50-70% of the bags did contain visible particles. BioE was unable to sell the lot, and, also, had to warn customers that some contaminated bags had been mixed into another set, which had been sent to customers and had reached end-users.
During this time, DeOlden and other Mediatech representatives maintained that the particles were not caused by Mediatech's processes. In March 2009, DeOlden drafted and sent a written report to BioE and ASI, a supplier, which laid out the steps Mediatech had taken to identify the source of the contamination and concluded that Mediatech had not caused the contamination. DeOlden made the same claim during several telephone conversations with BioE.
Mediatech later determined that a component part of the bag sets it was purchasing from a supplier in China and providing to the subcontractor were contaminated. In September 2009, Mediatech determined that another likely source of the particle contamination was an S-shaped pipe on its filling equipment that it had not inspected or cleaned.
As part of the joint effort to identify the source of the particle contamination, ASI, Mediatech, and BioE all inspected validation lots of bag sets. ASI identified visible particles in 55% of the sets; Mediatech identified visible particles in only 0.5% of the same sets. BioE examined only a portion of the bag sets in these validation lots and identified contamination in 23%. From October 2009 through December 2009, Mediatech continued producing and delivering bag sets to BioE, of which BioE rejected approximately 5-15% due to contamination. Finally, on December 16, 2009, BioE received two letters from Mediatech indicating that the Mediatech employee inspecting the validation lots and returned Products had bad eyesight and could not see particles that others could see.
On May 18, 2010, BioE filed a Complaint against Mediatech and DeOlden in this Court. On July 23, 2010, BioE filed an Amended Complaint against Mediatech and DeOlden, which alleges: Count I: Negligence (Mediatech); Count II: Breach of Contract (Mediatech); Count III: Misrepresentation (Mediatech and DeOlden); and Count IV: Negligent Retention and Supervision (Mediatech and DeOlden).
Defendants now move that all claims against DeOlden must be dismissed because this Court lacks personal jurisdiction over him; that the negligent misrepresentation claims against DeOlden and Mediatech be dismissed for failure to plead with particularity and failure to state a claim upon which relief can be granted; and that the negligent retention and supervision claims against DeOlden be dismissed for failure to state a claim upon which relief can be granted.
While the plaintiff eventually bears the burden to establish personal jurisdiction by preponderance of the evidence, when personal jurisdiction is decided based upon affidavits, prior to an evidentiary hearing, the plaintiff need only establish a prima facie showing of personal jurisdiction.
"A two-step inquiry is employed when determining whether a federal court has jurisdiction over a non-resident party: (1) whether the facts presented satisfy the forum state's long-arm statute, and (2) whether the nonresident has `minimum contacts' with the forum state, so that the court's exercise of jurisdiction would be fair and in accordance with due process."
The Eighth Circuit has explained:
In order to determine whether the exercise of jurisdiction comports with due process, the Court examines five factors:
In
A court can exercise either specific or general personal jurisdiction over a party. "Specific jurisdiction refers to jurisdiction over causes of action arising from or related to a defendant's actions within the forum state, while [g]eneral jurisdiction . . . refers to the power of a state to adjudicate any cause of action involving a particular defendant, regardless of where the cause of action arose."
DeOlden argues that he is not subject to personal jurisdiction in Minnesota because only his contacts, not Mediatech's, may be considered, and he has visited the state only once, 10-12 years ago, on a trip unrelated to the present litigation. He owns no property or real estate in Minnesota, and has no possessions here.
He further argues that although he is the president of Mediatech, he was not a signatory to any contract between Mediatech and BioE. According to DeOlden, he did not make personal representations to BioE on behalf of Mediatech, was merely a peripheral participant in conference calls between the companies' employees, and his only direct contacts with BioE were telephone calls related to BioE's threats of litigation.
To the extent that DeOlden is arguing that he is insulated because his only contacts with Minnesota were in his official capacity, the United States Supreme Court has explicitly "reject[ed] the suggestion that employees who act in their official capacity are somehow shielded from suit in their individual capacity" as a matter of due process.
At this stage, taking the facts in the light most favorable to BioE, DeOlden played an active role in the companies' relationship and in Mediatech's manufacture of the specific product at issue here. He knew BioE was located in Minnesota. He actively participated in more than 20 teleconferences with BioE representatives in 2006, 2007, and the first half of 2009. He met with BioE representatives when they visited Virginia on three occasions. He also drafted and sent to BioE a report detailing Mediatech's conclusions regarding the source of the contamination in the bags. On several occasions, he falsely represented to BioE that Mediatech had solved the particulate problem. These are ample contacts, aimed at BioE, in Minnesota, that weigh in favor of personal jurisdiction.
To satisfy specific jurisdiction, there must be a connection between the cause of action and the defendant's contacts with the forum state. In this instance, DeOlden's communications with BioE represent the bulk of his contacts with Minnesota, and were the vehicle for the alleged misrepresentations that form the core of BioE's reckless misrepresentation claim. This factor weighs in favor of personal jurisdiction.
Minnesota has an interest in providing a forum for its residents to seek redress for alleged fraud against them.
DeOlden argues that the convenience of the parties weighs against jurisdiction because of his physical condition and the distance between Minnesota and his home in Virginia. He asserts that every seven to ten weeks, he becomes incapacitated with a severe bout of Meniere's Disease that leaves him with episodes of headaches, vomiting, and vertigo.
DeOlden's condition will affect him whether he is in Virginia or Minnesota, and that the parties and Court will accommodate his illness in either case. DeOlden's health issue is not a compelling reason for this Court to decline jurisdiction. Moreover, while Virginia would be a more convenient forum for DeOlden, Minnesota is a more convenient forum for BioE and its witnesses. This factor weighs in favor of jurisdiction.
Finally, the outcome of the
Because all factors weigh in favor of personal jurisdiction over DeOlden, the Court denies DeOlden's motion to dismiss for lack of personal jurisdiction.
Under Rule 12(b)(6) of the Federal Rules of Civil Procedure, a party may move the Court to dismiss a claim if, on the pleadings, a party has failed to state a claim upon which relief may be granted. In reviewing a motion to dismiss, the Court takes all facts alleged in the complaint to be true.
In deciding a motion to dismiss, the Court considers "the complaint, matters of public record, orders, materials embraced by the complaint, and exhibits attached to the complaint."
"Negligent supervision is the failure of an employer to exercise ordinary care in supervising the employment relationship so as to prevent foreseeable misconduct of an employee from causing harm to others."
Under Minnesota law, as explained by this Court in
Similarly, actual or threatened physical injury is "[a]n essential element of a negligent retention claim."
Here, the only harm alleged to BioE is financial. The "potential bodily injury" noted in the Complaint relates to potential injuries to third parties, who, in turn, might assert claims against BioE that, if successful, would cause BioE financial—not physical—harm. When the Court raised this issue during oral argument, Plaintiff was unable to point to any potential for physical injury to itself.
The Court dismisses Count IV for failure to state a claim because no physical injury or threat of physical injury to Plaintiff is alleged.
The elements of reckless misrepresentation are:
Minnesota law considers an allegation of misrepresentation, "whether labeled as a claim of fraudulent misrepresentation or negligent misrepresentation [to be] an allegation of fraud which must be pled with particularity," and such a claim is subject to Federal Rule of Civil Procedure 9(b).
The Court agrees with Defendants that BioE's allegations of misrepresentation are not pleaded with sufficient particularity. BioE's complaint leaves Defendants unable to identify and defend against the alleged misrepresentations.
In its brief, BioE points to eight alleged misrepresentations in its Amended Complaint. Because the timing and context of the statements is relevant to what, if any, reasonable reliance was induced and what, if any, injury was caused, the Court analyzes the alleged misrepresentations in chronological order.
The first allegation, which covers two separate paragraphs of the Amended Complaint, does not identify a time, a place, the identity of the person making the misrepresentation, nor what was obtained or given up.
The content of the second alleged misrepresentation is adequately pleaded, but BioE does not identify the time (other than a period spanning several years), or the place (except an unidentified number of phone conversations and meetings). Because the timing is unclear, Defendants cannot discern whether some of these alleged misrepresentations occurred before the product specifications were defined and, therefore, are pre-contract statements of opinion or promises of future performance regarding quality control standards not yet decided.
BioE alleges reliance generally and also alleges that, after it discovered that the Product was contaminated, it "reasonably relied" on the misrepresentations "in continuing to work with Mediatech." (Am. Compl. ¶ 1.) BioE also argues that, because of the false certifications, it had to ask customers to return unused products from two lots previously certified by Mediatech. (Am. Compl. ¶ 5.) These allegations of reliance do not apply to pre-contract misrepresentations, but rather are limited to misrepresentations made after the contract was signed and the contamination was discovered. There could be no reliance in continuing the relationship if the representation was made before the contract was signed. Also, if representations regarding quality control were made before the specifications were actually agreed to, then the statements would appear to be vague puffery. Therefore, the Court dismisses the claims listed in the "Unknown Timing" section for failure to plead fraud with particularity.
BioE alleges that three misrepresentations by Mediatech and DeOlden occurred before the companies entered a contract:
BioE adequately identifies the time, place, content, and speaker for each of these representations. However, it does not specifically identify what was given up or obtained as a result of the alleged misrepresentations. BioE argues that its allegation of reliance is found in the first paragraph of the Amended Complaint. However, as the Court has explained, this paragraph it is not directed at these pre-contract statements. And even if that allegation of reliance did refer to these three statements, it still does not identify what was given up or obtained. BioE does not allege that it entered the relationship with Mediatech in reliance on alleged misrepresentations, only that the misrepresentations caused it to forego ending the relationship after contamination was already discovered and that, once the problem occurred, the misrepresentations caused delay.
Additionally, the first and third allegations are pre-contract puffery because they were made before BioE had set its specifications. Both statements are opinions of Mediatech's capabilities relative to as-yet-unknown standards. BioE fails to state how they were false statements at the time they were made — only alleging that the statements later turned out to be false. Thompson's statement that Mediatech's machinery did not cause heating is a statement of present fact, but it is unclear how BioE relied upon that statement.
BioE also alleges three misrepresentations made at specific times after it entered the contract with Mediatech:
Each of these allegations identifies DeOlden as the person making the representation and the content of the representation. However, other flaws appear in the allegations.
The first allegation purports to identify July 2006 as the time at which the representation was made. However, the Amended Complaint indicates that the process changes DeOlden claimed had solved the denatured protein problem could not have been instituted until at least a month after he allegedly made the claim: BioE began clinical testing in August 2006. During clinical testing, Mediatech produced product with white particles. Mediatech "soon" determined that the white particles were denatured protein, after which it attempted to fix the problem by changing its processes. Thus, either the alleged time of DeOlden's representation is incorrect or the content of the misrepresentation is not as claimed.
The second allegation does plead with particularity the time, place, contents, and identity of the person making the alleged misrepresentation. BioE claims DeOlden's statements were "made recklessly," which is an adequate allegation of scienter. However, BioE does not allege that it relied on the report, nor does it specify what was given up or obtained as a result of the alleged misrepresentation in the report.
As to the third allegation, BioE, by its own admission, did not rely upon Defendants' assertions that the particle problems were resolved, since BioE alleges that, while Defendant were making these statements, BioE was conducting its own visual inspections and was rejecting 5-15% of all Product delivered by BioE. Nor does BioE identify what was obtained or given up as a result of the misrepresentations: the alleged misrepresentation occurred after BioE had instituted its own quality control inspections.
In conclusion, the Court dismisses Count III without prejudice as to both Defendants. Overall, it is unclear which particular statements form the basis for BioE's misrepresentation claim, when those statements were made, and how BioE relied on and was damaged by those statements. The dismissal of Count III is without prejudice in order to provide Plaintiff one more chance to clarify its allegations.
Accordingly, based upon the files, records, and proceedings herein,